Ruijia Zhou, Shiyin Chen, Qiwen Wu, Lingyun Liu, Yian Wang, Yongzhen Mo, Zhaoyang Zeng, Xuyu Zu, Wei Xiong, Fuyan Wang
In recent years, there have been multiple breakthroughs in cancer immunotherapy, with immune checkpoint inhibitors becoming the most promising treatment strategy. However, available drugs are not always effective. As an emerging immune checkpoint molecule, CD155 has become an important target for immunotherapy. This review describes the structure and function of CD155, its receptors TIGIT, CD96, and CD226, and summarizes that CD155 expressed by tumor cells can upregulate its expression through the DNA damage response pathway and Ras-Raf-MEK-ERK signaling pathway...
October 1, 2023: Cancer Letters